{"filings":[{"id":1138598,"accession_number":"0001193125-26-275879","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2026-06-18T20:13:20+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Agios shareholders elect three Class I directors, approve 2M share increase to stock plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Rahul Ballal, Brian Goff, and Cynthia Smith as Class I directors for three-year terms expiring 2029.","Advisory vote on executive compensation approved: 43.4M for, 1.1M against, 1.6M abstain.","Stockholders approved amendment to 2023 Stock Incentive Plan, increasing authorized shares by 2,000,000.","Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal year 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92890,"accession_number":"0001439222-26-000071","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q1 mitapivat revenue $20.7M; 242 AQVESME scrips; sCD sNDA plan in Q2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide mitapivat net revenue $20.7M in Q1 2026, up from $8.7M in Q1 2025.","242 AQVESME prescriptions for thalassemia by U.S. REMS-certified physicians as of March 31, 2026.","Plans to submit mitapivat sNDA for sickle cell disease under accelerated approval pathway in Q2 2026.","Net loss $99.1M in Q1 2026 vs $89.3M in Q1 2025.","Cash and equivalents $1.0B as of March 31, 2026, down from $1.2B at Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":20746000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104086,"accession_number":"0001439222-26-000023","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q4 net loss $108M; AQVESME approved for thalassemia, U.S. launch started","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PYRUKYND worldwide net revenue $20M in Q4 ($16M U.S., $4M ex-U.S.), up 49% YoY in U.S.","Full-year 2025 PYRUKYND revenue $54M; net loss $108M in Q4 vs $96.5M in Q4 2024.","FDA approved AQVESME (mitapivat) for thalassemia in Dec 2025; U.S. launch began late Jan 2026.","Pre-sNDA meeting with FDA for mitapivat in sickle cell disease expected Q1 2026.","Phase 2 tebapivat trial in sickle cell disease fully enrolled; topline data in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":54028000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104085,"accession_number":"0001439222-26-000018","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Agios outlines 2026 milestones: AQVESME launch in thalassemia, potential sNDA for sickle cell disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AQVESME (mitapivat) U.S. approval in thalassemia Dec 2025; commercial launch underway, product available late Jan 2026.","Pre-sNDA meeting with FDA for mitapivat in sickle cell disease expected Q1 2026; U.S. submission to follow.","Pipeline: tebapivat Phase 2 sickle cell topline H2 2026; Phase 2b LR-MDS topline H1 2026.","AG-236 (siRNA for PV) Phase 1 healthy volunteer topline H1 2026; AG-181 Phase 1b PKU trial init H1 2026.","Target >$1B peak global sales from existing thalassemia and PK deficiency commercial presence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120366,"accession_number":"0001439222-25-000114","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q3 PYRUKYND rev $12.9M (+44% YoY); net loss $103.4M; thalassemia PDUFA Dec 7","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 PYRUKYND net revenue $12.9M (+44% YoY vs $9.0M); 149 U.S. patients on therapy.","Net loss $103.4M in Q3 2025 vs net income $947.9M in Q3 2024 (prior-year milestone payments).","Cash $1.3B; PDUFA goal date Dec 7, 2025 for PYRUKYND sNDA in thalassemia.","CHMP positive opinion for PYRUKYND in thalassemia; EC decision expected early 2026.","RISE UP Phase 3 sickle cell disease topline results by year-end; tebapivat Phase 2b topline early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":34061000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136942,"accession_number":"0001439222-25-000090","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Agios responds to analyst report on PYRUKYND safety data; Saudi Arabia approves PYRUKYND for thalassemia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Analyst report on Aug 4, 2025 references four FAERS cases; Agios says benefit-risk profile unchanged.","Three cases reported to Agios: two for PK deficiency patients on commercial PYRUKYND, one expanded access for sickle cell.","Fourth case reported directly to FDA; Agios evaluating via pharmacovigilance processes.","Saudi FDA approved PYRUKYND for adult patients with alpha- or beta-thalassemia (both non-transfusion and transfusion dependent)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136941,"accession_number":"0001439222-25-000087","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q2 2025 net loss $112M; PYRUKYND revenue $12.5M; PDUFA Sept 7 for thalassemia","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $112.0M vs $96.1M YoY; PYRUKYND net revenue $12.5M, up from $8.6M in Q2 2024.","Cash and marketable securities $1.3B; expects to fund potential thalassemia and SCD launches.","FDA PDUFA goal date for PYRUKYND sNDA in thalassemia is Sept 7, 2025; launch prep underway.","RISE UP Phase 3 topline for mitapivat in sickle cell disease on track by year-end 2025.","Dosed first patient in tebapivat Phase 2 for SCD; IND clearance for AG-236 siRNA for PV."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":21181000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136940,"accession_number":"0001439222-25-000076","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Agios Pharmaceuticals elects Jay Backstrom, M.D., MPH to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Backstrom appointed as Class III director, term until 2028 Annual Meeting.","Appointed to Science and Technology Committee of the Board effective July 8, 2025.","Initial compensation includes stock option with $472,500 Black-Scholes value and RSUs valued at $157,500.","Annual cash compensation: $50,000 for board service plus $7,500 for committee service, quarterly pro-rata."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154199,"accession_number":"0001193125-25-142745","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Agios shareholders elect two directors, approve 2.5M share plan increase and say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors Jacqualyn A. Fouse and David Scadden elected with 45.96M and 46.20M votes for, respectively.","Non-binding say-on-pay approved: 46.84M for, 3.02M against, 16,430 abstain.","2023 Stock Incentive Plan amendment approved: 31.68M for, 18.20M against (36.5% opposition), adding 2.5M authorized shares.","Ratification of PricewaterhouseCoopers as auditor: 51.20M for, 136,734 against, 22,781 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154198,"accession_number":"0001439222-25-000034","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q1 PYRUKYND revenue $8.7M; PDUFA Sept 7 for thalassemia; net loss $89.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PYRUKYND net revenue $8.7M in Q1 2025 vs $8.2M in Q1 2024; 136 patients on therapy.","FDA accepted sNDA for thalassemia with PDUFA goal date September 7, 2025; no advisory committee planned.","Phase 3 RISE UP in sickle cell disease topline results expected late 2025; potential US launch in 2026.","Net loss $89.3M in Q1 2025 vs $81.5M in Q1 2024; cash and securities $1.4B as of March 31, 2025.","Krishnan Viswanadhan appointed Chief Corporate Development and Strategy Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":8726000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172793,"accession_number":"0001439222-25-000007","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q4: PYRUKYND revenue $10.7M, mitapivat PDUFA Sept 7, 2025; cash $1.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PYRUKYND net revenue $10.7M in Q4 (+20% QoQ), full year $36.5M vs $26.8M in 2023.","Filed for mitapivat approval in thalassemia in US, EU, KSA, UAE; PDUFA goal date Sept 7, 2025.","Phase 3 RISE UP for sickle cell disease fully enrolled (>200 patients); topline results late 2025, potential launch 2026.","Cash, cash equivalents and marketable securities $1.5B as of Dec 31, 2024; net loss Q4 $96.5M, full year net income $673.7M.","Board member David Schenkein to step down effective Feb 28, 2025; remains as strategic advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":11.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":36498000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172792,"accession_number":"0001193125-25-025524","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Agios board member David Schenkein resigns effective Feb 28, 2025; stays as strategic advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Schenkein notified company of resignation from board on Feb 10, 2025, effective Feb 28, 2025.","He will also cease serving on the Science and Technology Committee of the board.","He will continue as a strategic advisor to leadership, focusing on advancing clinical development programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172791,"accession_number":"0001193125-25-004943","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Agios announces 2025 milestones: PYRUKYND PDUFA Sept 7; RISE UP topline in late 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA accepted sNDA for PYRUKYND in thalassemia; PDUFA goal date September 7, 2025.","Phase 3 RISE UP topline results expected late 2025; potential U.S. commercial launch in 2026.","Received $1.1B in milestone payments: $905M from Royalty Pharma, $200M from Servier post vorasidenib approval.","Phase 3 ACTIVATE-Kids topline in early 2025; Phase 2b tebapivat enrollment completion late 2025.","IND filing planned for AG-236 siRNA in polycythemia vera mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172790,"accession_number":"0001193125-25-001809","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"FDA adds liver injury warning to PYRUKYND label for PK deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved update to PYRUKYND USPI: liver injury observed in patients with another condition at higher doses.","New Warnings: obtain liver tests before initiation, monthly for first 6 months, interrupt if ALT >5x ULN.","All patients with liver injury discontinued PYRUKYND and improved upon discontinuation.","Adverse Reactions section updated to reflect hepatocellular injury in another condition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189808,"accession_number":"0001439222-24-000136","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios reports Q3 net income of $947.9M on $1.1B milestone payments; PYRUKYND rev $9.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $947.9M vs loss $91.3M YoY; driven by $1.1B payments from Royalty Pharma & Servier.","PYRUKYND net revenue $9.0M (+4% QoQ); 127 patients on therapy, 211 enrollment forms.","Completed enrollment of Phase 3 RISE UP for mitapivat in SCD; topline data expected late 2025.","Initiated Phase 2b of tebapivat in LR-MDS; FDA orphan drug designation for MDS received.","Cash, equivalents and securities $1.7B at Sept 30, 2024, up from $806.4M at Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":13.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":25768000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206313,"accession_number":"0001439222-24-000117","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q2 2024 net loss $96.1M; PYRUKYND rev $8.6M; plans thalassemia sNDA by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PYRUKYND net revenue $8.6M in Q2 2024, up 5% sequentially; 128 patients on therapy.","Net loss $96.1M vs $83.8M YoY; cash, equivalents, marketable securities $645.3M at June 30.","Phase 3 ENERGIZE-T met primary endpoint in transfusion-dependent thalassemia; sNDA filing planned by end of 2024.","Announced $905M purchase agreement with Royalty Pharma for vorasidenib royalty; total $1.1B payable upon FDA approval.","Announced ACTIVATE-KidsT topline data in pediatric PK deficiency; ACTIVATE-Kids enrollment complete, data in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":16804000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223415,"accession_number":"0001193125-24-164555","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Agios shareholders elect four Class II directors, approve say-on-pay, ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Kaye Foster (45.8M for, 5.3M withheld), Maykin Ho (46.7M for, 4.4M withheld), Jeffrey Capello (47.8M for, 3.3M withheld), Catherine Owen (45.6M for, 5.5M withheld) as Class II directors.","Advisory vote on named executive officer compensation approved: 48.0M for, 3.1M against, 13,404 abstaining.","Ratified PricewaterhouseCoopers LLP as independent auditor: 52.3M for, 70,843 against, 2,396 abstaining."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223414,"accession_number":"0001193125-24-147583","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Agios sells vorasidenib royalty rights to Royalty Pharma for $905M upfront upon FDA approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalty Pharma pays $905M to Agios upon FDA approval of vorasidenib (PDUFA date Aug 20, 2024).","Agios retains $200M milestone from Servier upon approval; total potential cash inflow of ~$1.1B.","Royalty Pharma receives 15% royalty on first $1B annual US sales; Agios retains 3% on sales above $1B.","Proceeds intended to fund PYRUKYND launches in thalassemia/sickle cell and expand pipeline.","Transaction closing requires FDA approval by Oct 31, 2024 and other customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223413,"accession_number":"0001439222-24-000067","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q1 2024 PYRUKYND revenue $8.2M; net loss $81.5M; mitapivat ENERGIZE-T readout Q2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PYRUKYND net revenue $8.2M in Q1 2024, up 15% sequentially; 120 patients on therapy.","Net loss $81.5M in Q1 2024 vs $81.0M in Q1 2023; cash $714.3M as of March 31, 2024.","Positive Phase 3 ENERGIZE results for mitapivat in non-transfusion-dependent thalassemia announced in January.","ENERGIZE-T topline data expected Q2 2024; FDA filing for mitapivat in thalassemia planned year-end.","Servier's vorasidenib NDA accepted with PDUFA Aug 20, 2024; Agios eligible for $200M milestone and 15% royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":8189000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242865,"accession_number":"0001439222-24-000032","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q4 net loss $95.9M; positive mitapivat Phase 3 for NTD thalassemia","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 PYRUKYND US net revenue $7.1M (down 4% QoQ); full year 2023 $26.8M.","Net loss $95.9M in Q4 vs net income $36.5M in Q4 2022; full year loss $352.1M.","Positive Phase 3 ENERGIZE study in non-transfusion-dependent thalassemia met primary endpoint.","Cash & equivalents $806.4M; company expects runway into 2026.","Pipeline milestones: ENERGIZE-T data mid-2024; FDA filing for mitapivat in thalassemia end-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":26823000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242864,"accession_number":"0001193125-24-003920","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Agios outlines 2024 milestones; positive Phase 3 mitapivat data in thalassemia; multiple potential approvals by 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent thalassemia met primary endpoint (data Jan 3, 2024).","NDA for mitapivat in thalassemia planned by end of 2024; potential FDA approval in 2025.","Four additional Phase 3 readouts expected by end of 2025: ENERGIZE-T, ACTIVATE kids-T, RISE UP, ACTIVATE kids.","Potential FDA approvals: thalassemia 2025, sickle cell disease 2026, pediatric PK deficiency 2026.","Cash position expected to support operations and pipeline expansion at least into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260232,"accession_number":"0001439222-23-000138","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q3: PYRUKYND rev $7.4M; first patient dosed in Phase 3 sickle cell; net loss $91.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PYRUKYND net revenue $7.4M in Q3 2023 (+10% QoQ); 100 patients on therapy, 160 completed enrollment forms.","First patient dosed in Phase 3 portion of RISE UP pivotal study of mitapivat in sickle cell disease.","Completed enrollment in Phase 3 ACTIVATE-kidsT; >50% enrolled in Phase 3 ACTIVATE-kids for pediatric PK deficiency.","Net loss $91.3M in Q3 2023 vs $81.7M in Q3 2022; cash $872.4M as of Sep 30, 2023, funding into 2026.","Topline data for AG-946 in LR-MDS expected by year-end 2023; Phase 3 thalassemia data in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":19720000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277524,"accession_number":"0001439222-23-000117","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q2 2023: PYRUKYND revenue $6.7M; net loss $83.8M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PYRUKYND net revenue $6.7M in Q2, up 20% QoQ; 147 patients completed enrollment forms, 99 on therapy.","Net loss $83.8M vs $91.8M a year ago; cash $946.9M, expected runway into 2026.","Phase 2 mitapivat in sickle cell positive; Phase 3 enrollment to begin Q4 2023.","Completed enrollment in Phase 3 thalassemia studies (ENERGIZE/ENERGIZE-T) and Phase 2a AG-946 in LR-MDS.","Licensed Alnylam siRNA for polycythemia vera; appointed Catherine Owens to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":12321000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295471,"accession_number":"0001193125-23-166855","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Agios stockholders approve 2023 Stock Incentive Plan; elect three Class I directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Rahul Ballal, Brian Goff, and Cynthia Smith as Class I directors for terms expiring at the 2026 annual meeting.","2023 Stock Incentive Plan approved with 27,268,226 votes for, 23,635,666 against, and 25,531 abstentions.","Non-binding advisory vote on named executive officer compensation passed (46,289,192 for, 4,630,627 against).","PricewaterhouseCoopers LLP ratified as independent auditor for fiscal 2023 (50,024,364 for, 1,876,012 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295470,"accession_number":"0001193125-23-154190","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Agios director John Maraganore resigns; Catherine Owen elected to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Maraganore resigned from board effective May 24, 2023, after nearly 12 years.","Kaye Foster appointed lead independent director; Cynthia Smith becomes Compensation & People Committee chair.","Catherine Owen elected as class II director effective June 13, 2023; joins Compensation & People Committee.","Owen receives annual cash: $50,000 as director plus $7,500 for committee service.","Owen granted initial equity: nonstatutory option with $472,500 Black-Scholes value and RSUs valued at $157,500."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295469,"accession_number":"0001439222-23-000063","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q1 2023: PYRUKYND revenue $5.6M, net loss improves to $81M, cash $1.0B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PYRUKYND net revenue of $5.6M in Q1 2023; 127 unique patients enrolled, 89 on therapy.","Net loss of $81.0M improved from $94.8M in Q1 2022; R&D expense $67.3M, SG&A $28.4M.","Cash, cash equivalents and marketable securities $1.0B as of March 31, 2023.","Phase 2 sickle cell data (RISE UP) expected mid-2023; ENERGIZE/ENERGIZE-T enrollment closed.","Appointed Jeffrey Capello to board; Paul Clancy stepping down effective June 13, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":5609000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295468,"accession_number":"0001193125-23-105679","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2023-04-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Agios director Paul Clancy to retire; Jeff Capello elected to board, to chair Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Clancy will not stand for re-election at 2023 Annual Meeting; ceases as Audit Committee chair and Compensation & People Committee member.","Jeff Capello elected as class II director effective at 2023 Annual Meeting; appointed Audit Committee chair.","Capello receives $50,000/yr director cash retainer plus $20,000/yr for Audit Chair role; initial equity grant of stock options ($472,500 Black-Scholes) and RSUs ($157,500).","Capello enters into standard indemnification agreement with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316018,"accession_number":"0001193125-23-060031","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Agios Pharmaceuticals amends bylaws to update proxy rules and meeting procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Revised procedural mechanics for stockholder nominations under universal proxy rules.","Requires additional background info and representations from proposing stockholders.","Clarifies that failure to comply with Rule 14a-19 may result in disregarding nominations.","Eliminates requirement to make stockholder list available during meeting.","Adds emergency provisions limiting officer/director liability to willful misconduct."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316017,"accession_number":"0001439222-23-000037","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q4 2022 net income $36.5M on PYRUKYND revenue $4.3M; cash $1.1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PYRUKYND net revenue $4.3M in Q4 2022, $11.7M full year; 78 patients on therapy, up 39% QoQ.","Net income from continuing ops $36.5M in Q4 vs loss $98.6M in Q4 2021; full-year net loss $231.8M.","Cash, equivalents and marketable securities $1.1B as of Dec 31, 2022, down from $1.3B year-end 2021.","Completed enrollment in Phase 2 RISE UP sickle cell study; on track to complete Phase 3 thalassemia enrollment by mid-2023.","Appointed Tsveta Milanova as chief commercial officer; received EU and Great Britain approvals for PYRUKYND."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":14240000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316016,"accession_number":"0001193125-23-004143","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Agios unveils 2023-2026 catalysts: PYRUKYND approvals, pipeline expansion, cash-flow positivity by 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Five ongoing pivotal PYRUKYND trials in thalassemia, sickle cell, and pediatric PK deficiency.","Potential FDA approvals: thalassemia 2025, sickle cell 2026, pediatric PK deficiency 2026.","Expects to complete ENERGIZE/ENERGIZE-T enrollment by mid-2023; RISE UP Phase 2 data and go/no-go by mid-year.","AG-946 Phase 2a enrollment in LR-MDS completed by year-end 2023; IND filing for PAH stabilizer in PKU planned.","Appointed Tsveta Milanova as CCO; EU/Great Britain approval for PYRUKYND in adult PK deficiency already received."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334317,"accession_number":"0001193125-22-307300","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Agios adopts performance-based cash bonus for CMO tied to ENERGIZE trial milestone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Sarah Gheuens, CMO and Head of R&D, eligible for up to 1.25x her 2022 target bonus ($309,375) if ENERGIZE trial milestone achieved by April 2024.","If milestone achieved before April 2024, bonus increases to 1.2x the baseline amount, totaling $371,250.","Bonus payment contingent on Dr. Gheuens remaining employed at time of milestone achievement.","CEO, CFO, and Chief Commercial Officer are not eligible for this bonus plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334316,"accession_number":"0001193125-22-298895","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Agios appoints Tsveta Milanova as CCO effective Jan 3, 2023; Richa Poddar departs Dec 31, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tsveta Milanova named Chief Commercial Officer, will succeed Richa Poddar effective Jan 3, 2023.","Milanova previously SVP US Commercial at Alexion; brings rare disease commercial launch experience.","Poddar will receive $450K severance plus 2022 target bonus and 12-month COBRA coverage.","Milanova's base salary $510K, target bonus 45%, sign-on bonus $150K, plus equity grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334315,"accession_number":"0001439222-22-000098","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q3 2022: PYRUKYND revenue $3.5M, 56 patients on therapy; CHMP positive opinion received","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PYRUKYND net revenue $3.5M in Q3 2022; 56 patients on therapy (+51% Q/Q), 84 patients enrolled (+64%).","Received positive CHMP opinion for PYRUKYND in adult PK deficiency; filed with UK MHRA.","Cash $1.0B as of Sept 30; subsequently received $131.8M from sale of TIBSOVO royalty rights.","Net loss from continuing ops $81.7M vs $84.3M in Q3 2021; R&D $65.0M, SG&A $29.1M.","Appointed Cecilia Jones as CFO; Rahul Ballal and Cynthia Smith to board of directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":9930000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334314,"accession_number":"0001193125-22-270979","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Agios sells TIBSOVO royalty rights to Sagard for $131.8M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront cash payment of $131.8M for 5% royalty on U.S. net sales of TIBSOVO (ivosidenib).","Agios retains $200M milestone for vorasidenib and 15% royalties on its U.S. net sales.","Deal provides non-dilutive capital to fund PYRUKYND launch and ongoing pipeline programs.","Transaction closed on October 27, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334313,"accession_number":"0001193125-22-259591","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-10-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Agios amends severance plan; expands C-Level definition, alters equity vesting rules","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["C-Level Employee definition expanded to include any job title above Senior Vice President.","New-Hire Equity Awards granted after October 6, 2022 will have accelerated vesting on non-Change-of-Control termination or death/disability.","Change-of-Control Termination now triggers full vesting of service-based equity awards; performance awards per original plan terms.","Post-Change-of-Control amendment/termination restriction period increased from 12 to 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351746,"accession_number":"0001193125-22-246740","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-09-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Agios appoints Cecilia Jones as CFO effective Sept 26; replaces Jonathan Biller","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cecilia Jones appointed CFO, effective Sept 26, 2022, replacing Jonathan Biller who resigned Sept 16 to become CLO at Vertex.","Jones previously CFO at LogicBio; 10+ years at Biogen in various finance roles including VP of R&D and BD finance.","Compensation: $475k base salary, 45% target annual bonus, $1.875M stock option, $625k RSUs, $300k PSUs.","Stock option vests: 25% on first anniversary, then monthly through year 4; RSUs vest equally over 3 years.","Company highlights PYRUKYND commercial launch and five pivotal trials; Jones to lead financial strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351745,"accession_number":"0001193125-22-239454","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-09-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Agios Pharma CFO Jonathan Biller resigns effective Sept 16","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jonathan Biller notified resignation as CFO, head of corporate affairs, effective Sept 16, 2022.","Resignation is to pursue other opportunities; no successor named as of filing date.","Biller served as principal financial officer; departure creates CFO vacancy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351744,"accession_number":"0001193125-22-221224","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Agios Pharmaceuticals elects Rahul Ballal and Cynthia Smith as new directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board elected Rahul Ballal, Ph.D. and Cynthia Smith as Class I directors on Aug 11, 2022, effective immediately.","Each new director receives annual cash compensation of $50,000 and initial equity grants: 37,947 options at $25.99 and 6,906 RSUs.","Options vest 25% on first anniversary, remainder over 36 months; RSUs vest 1/3 annually over three years.","Both directors entered standard indemnification agreements with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351743,"accession_number":"0001193125-22-211808","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q2 2022: PYRUKYND revenue $3.1M; net loss $91.8M; CEO transition to Brian Goff","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2022 net loss from continuing ops $91.8M vs $82.8M Q2 2021; R&D expenses rose to $74.5M.","PYRUKYND generated $3.1M net U.S. revenue in first full quarter after Feb 2022 FDA approval.","Cash, equivalents, marketable securities $1.1B, down from $1.7B; expects to fund to cash-flow positivity.","Brian Goff becomes CEO Aug 8; current CEO Jackie Fouse transitions to Chair of Board.","Five pivotal PYRUKYND studies enrolling across thalassemia, sickle cell, pediatric PK deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":6414000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351742,"accession_number":"0001193125-22-192006","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-07-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Agios appoints Brian Goff as CEO; Jackie Fouse transitions to Chair effective Aug 8, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Brian Goff appointed effective Aug 8, 2022; current CEO Jackie Fouse becomes Chair of Board.","Goff receives $775K base salary, 70% target bonus, equity grants: $9M options, $5M PSUs, $2M RSUs.","Goff also gets $250K relocation payment; equity awards vest over 3–4 years under Nasdaq inducement grant.","Fouse's unvested equity continues to vest; she will not receive director equity awards in 2022.","Former chair David Schenkein remains on board as director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369174,"accession_number":"0001193125-22-178757","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Agios shareholders elect directors, approve say-on-pay, ratify PwC at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Jacqualyn A. Fouse, David Scadden, David P. Schenkein as class III directors (48.5M, 48.5M, 45.4M votes for).","Advisory vote on executive compensation approved: 45.0M for, 4.5M against, 9K abstain.","Shareholders recommended say-on-pay every 1 year (48.7M votes); Board adopts annual frequency.","Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2022: 50.6M for, 140K against.","Broker non-votes of 1.17M on director elections and advisory items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369173,"accession_number":"0001193125-22-160979","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-05-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Agios CSO Bruce Car resigns, signs consulting agreement through March 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Bruce Car steps down as chief scientific officer effective August 1, 2022.","Consulting agreement runs from August 1, 2022 to March 31, 2023, extendable with consent.","Services limited to transition and research science support, not exceeding 10 hours per week.","Outstanding equity awards will continue to vest during the consulting term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369172,"accession_number":"0001193125-22-154024","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-05-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CSO Bruce Car resigns from Agios, effective July 31, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bruce Car, Ph.D., Chief Scientific Officer, notified his resignation on May 15, 2022.","Resignation effective July 31, 2022; no replacement named as of filing date.","Voluntary departure; no reason or disagreement disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369171,"accession_number":"0001193125-22-141306","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios reports Q1 net loss $94.8M; PYRUKYND launch revenue $0.8M, cash $1.2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA approved PYRUKYND for PK deficiency in Feb 2022; U.S. launch generated $0.8M net revenue in partial quarter.","Net loss from continuing ops $94.8M vs $90.9M YoY; R&D spend $70.1M, SG&A $31.5M.","Cash & securities $1.2B (down from $2.4B YoY) due to $802.5M share repurchases in 2021; no need for equity.","Key 2022 milestones: EMA decision on PYRUKYND by year-end, start pediatric PK studies mid-2022.","Phase 2a study of AG-946 in MDS to initiate by year-end; AG-946 Phase 1 sickle cell cohort started."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":832000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369170,"accession_number":"0001193125-22-120194","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-04-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Ian T. Clark resigns from Agios board effective after 2022 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ian T. Clark resigns as director effective immediately following the 2022 annual meeting.","Clark also steps down from Compensation & People and Nominating & Corporate Governance committees.","Company states resignation not related to any disagreement over operations, policies, or practices.","No replacement director announced as of April 25, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388388,"accession_number":"0001193125-22-051106","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q4 net loss $98.6M; FDA approved PYRUKYND for PK deficiency; cash $1.3B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $98.6M in Q4 2021 vs $84.5M in Q4 2020; full-year net loss $356.5M.","Received FDA approval for PYRUKYND (mitapivat), first therapy for hemolytic anemia in adults with PK deficiency.","Cash, cash equivalents and marketable securities $1.3B as of Dec. 31, 2021; expects to fund operations to cash-flow positivity.","Dosed first patients in three pivotal trials of PYRUKYND in thalassemia and sickle cell disease.","R&D expenses $73.3M in Q4 2021, up from $59.4M in Q4 2020 due to pivotal study start-up costs."],"consensus_eps_estimate":null,"consensus_eps_actual":26.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388387,"accession_number":"0001193125-22-009843","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2022-01-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Agios sets 2022 annual meeting for June 21; stockholder deadlines announced","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2022 annual meeting to be held virtually on June 21, 2022.","Deadline for Rule 14a-8 stockholder proposals for proxy inclusion is January 28, 2022.","Other proposals or director nominations must be submitted between January 20 and February 19, 2022.","Meeting date is more than 30 days after 2021 annual meeting, triggering adjusted deadline rules.","Proposals must comply with applicable laws and company bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406318,"accession_number":"0001193125-21-317685","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Agios Q3 net loss $88.8M; mitapivat gets FDA Priority Review with PDUFA Feb 17, 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $88.8M vs $99.0M in Q3 2020; R&D $64.0M up from $51.9M on trial start-up costs.","Cash $1.4B; expects to fund operations through cash-flow positivity without equity raise.","FDA granted Priority Review for mitapivat in PK deficiency; PDUFA date Feb. 17, 2022.","Initiated Phase 3 ENERGIZE and ENERGIZE-T for thalassemia; plan to start RISE UP sickle cell study by year-end.","Repurchased 5.3M shares at $47.94 avg; $800M+ of $1.2B buyback completed."],"consensus_eps_estimate":null,"consensus_eps_actual":27.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425331,"accession_number":"0001193125-21-236341","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Agios appoints T.J. Washburn as principal accounting officer effective Aug 1, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["T.J. Washburn, age 40, appointed principal accounting officer effective August 1, 2021.","Washburn had served as senior director, corporate accounting at Agios for the prior 4 years.","He holds a CPA and a BS in business administration from Babson College.","Prior experience includes roles at Ernst & Young, Cubist Pharmaceuticals, Raytheon, Rue La La, and PwC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425330,"accession_number":"0001193125-21-228150","cik":1439222,"company_name":"AGIOS PHARMACEUTICALS, INC.","ticker":"AGIO","form_type":"8-K","filed_at":"2021-07-29T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Agios Q2 net loss $86.2M, cash $1.7B; CMO retirement, mitapivat NDA submitted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $86.2M vs $90.5M; cash, cash equivalents and marketable securities $1.7B.","R&D expenses $62.0M (up from $54.1M) for start-up costs of Phase 3 trials and regulatory filings.","Completed NDA in U.S. and MAA in EU for mitapivat in adults with PK deficiency.","Chris Bowden to retire as CMO effective Sept 1; Sarah Gheuens to assume role.","Repurchased 10.5M shares for $529M at average price $50.41 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":27.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1732408079.5041926,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-07-29T23:59:59+00:00|425330"}